Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis

por Goodall, Ruth L., Sanders, Karen, Bronson, Gay, Gurumurthy, Meera, Torrea, Gabriela, Meredith, Sarah, Nunn, Andrew, Rusen, I. D.
Publicado 2022

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results

por Ng, Kamela Charmaine, Meehan, Conor Joseph, Torrea, Gabriela, Goeminne, Léonie, Diels, Maren, Rigouts, Leen, de Jong, Bouke Catherine, André, Emmanuel
Publicado 2018

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled t...

por Nunn, Andrew J, Rusen, ID, Van Deun, Armand, Torrea, Gabriela, Phillips, Patrick PJ, Chiang, Chen-Yuan, Squire, S Bertel, Madan, Jason, Meredith, Sarah K
Publicado 2014

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations

por Ng, Kamela C. S., van Deun, Armand, Meehan, Conor J., Torrea, Gabriela, Driesen, Michèle, Gabriëls, Siemon, Rigouts, Leen, André, Emmanuel, de Jong, Bouke C.
Publicado 2018

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings

por Van Deun, Armand, Bola, Valentin, Lebeke, Rossin, Kaswa, Michel, Hossain, Mohamed Anwar, Gumusboga, Mourad, Torrea, Gabriela, De Jong, Bouke Catharine, Rigouts, Leen, Decroo, Tom
Publicado 2022

Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda

por Ngabonziza, Jean Claude Semuto, Ssengooba, Willy, Mutua, Florence, Torrea, Gabriela, Dushime, Augustin, Gasana, Michel, Andre, Emmanuel, Uwamungu, Schifra, Nyaruhirira, Alaine Umubyeyi, Mwaengo, Dufton, Muvunyi, Claude Mambo
Publicado 2016

Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda

por Ssengooba, Willy, de Dieu Iragena, Jean, Komakech, Kevin, Okello, Iginitius, Nalunjogi, Joanitah, Katagira, Winceslaus, Kimuli, Ivan, Adakun, Susan, Joloba, Moses L, Torrea, Gabriela, Kirenga, Bruce J
Publicado 2021

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

por Ssengooba, Willy, Komakech, Kevin, Namiiro, Sharon, Byabajungu, Henry, Nalunjogi, Joanitah, Katagira, Winceslaus, Kimuli, Ivan, Joloba, Moses L, Adakun, Susan, Nakiyingi, Lydia, Torrea, Gabriela, Kirenga, Bruce J
Publicado 2021

Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study

por Kaniga, Koné, Aono, Akio, Borroni, Emanuele, Cirillo, Daniela Maria, Desmaretz, Christel, Hasan, Rumina, Joseph, Lavania, Mitarai, Satoshi, Shakoor, Sadia, Torrea, Gabriela, Ismail, Nazir Ahmed, Omar, Shaheed V.
Publicado 2020

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance

por Torrea, Gabriela, Ng, Kamela C. S., Van Deun, Armand, André, Emmanuel, Kaisergruber, Justine, Ssengooba, Willy, Desmaretz, Christel, Gabriels, Siemon, Driesen, Michèle, Diels, Maren, Asnong, Sylvie, Fissette, Kristina, Gumusboga, Mourad, Rigouts, Leen, Affolabi, Dissou, Joloba, Moses, De Jong, Bouke C.
Publicado 2019

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

por Goodall, Ruth L, Meredith, Sarah K, Nunn, Andrew J, Bayissa, Adamu, Bhatnagar, Anuj K, Bronson, Gay, Chiang, Chen-Yuan, Conradie, Francesca, Gurumurthy, Meera, Kirenga, Bruce, Kiria, Nana, Meressa, Daniel, Moodliar, Ronelle, Narendran, Gopalan, Ngubane, Nosipho, Rassool, Mohammed, Sanders, Karen, Solanki, Rajesh, Squire, S Bertel, Torrea, Gabriela, Tsogt, Bazarragchaa, Tudor, Elena, Van Deun, Armand, Rusen, ID
Publicado 2022

Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century

por Ngabonziza, Jean Claude S., Rigouts, Leen, Torrea, Gabriela, Decroo, Tom, Kamanzi, Eliane, Lempens, Pauline, Rucogoza, Aniceth, Habimana, Yves M., Laenen, Lies, Niyigena, Belamo E., Uwizeye, Cécile, Ushizimpumu, Bertin, Mulders, Wim, Ivan, Emil, Tzfadia, Oren, Muvunyi, Claude Mambo, Migambi, Patrick, Andre, Emmanuel, Mazarati, Jean Baptiste, Affolabi, Dissou, Umubyeyi, Alaine N., Nsanzimana, Sabin, Portaels, Françoise, Gasana, Michel, de Jong, Bouke C., Meehan, Conor J.
Publicado 2022